The treatment landscape of EGFR-mutated non-small cell lung cancer (NSCLC) continues to evolve beyond survival benefit toward improved CNS control, quality of life, and long-term treatment planning. “Lung Cancer Conference – From Evidence to Confidence” brings together leading experts to review the evolution of EGFR-TKI therapy and explore the scientific rationale, structural innovation, and clinical value of Aumolertinib. The program will cover emerging evidence in early-stage disease, real-world clinical experience, resistance management, and practical approaches to adverse event management. In addition, future opportunities in mutation-directed therapies and combination treatment strategies beyond EGFR will be discussed. Through evidence-based updates and expert exchange, this symposium aims to enhance clinical confidence and optimize treatment outcomes for patients with EGFR-mutated NSCLC.